» Articles » PMID: 37664553

Refractory Kaposiform Lymphangiomatosis Relieved by Splenectomy

Overview
Journal Front Pediatr
Specialty Pediatrics
Date 2023 Sep 4
PMID 37664553
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Kaposiform lymphangiomatosis (KLA) is a rare and complex lymphatic anomaly with a poor prognosis. There is no standard treatment, and drug therapies are the most common therapeutic method. However, some patients' symptoms become gradually aggravated despite medical treatment. Splenectomy may be an alternative option when pharmacological therapies are ineffective.

Materials And Methods: We reviewed and evaluated the cases of 3 patients with KLA who ultimately underwent splenectomy. Results: The lesions were diffusely distributed and involved the lungs and spleens of the 3 patients. Laboratory examinations revealed that all three patients had thrombocytopenia and reduced fibrinogen levels. All patients underwent symptomatic splenectomy after the medication failed. Surprisingly, their symptoms greatly improved. Histopathological investigation of the splenic lesions of the three patients confirmed the diagnosis of KLA. Immunohistochemical staining showed positivity for CD31, CD34, podoplanin, Prox-1 and angiopoietin 2 (Ang-2).

Discussion: This study aimed to review the features of KLA patients treated by splenectomy and explore the underlying link between splenectomy and prognosis. The reason for the improvement after splenectomy may be related to increased Ang-2 levels and platelet activation in patients with KLA. Future research should seek to develop more targeted drugs based on molecular findings, which may give new hope for the treatment of KLA.

Citing Articles

Clinical characteristics and risk factors for acute abdomen in patients with abdominal lymphatic malformations.

Yang C, Qiu T, Yang M, Zhou J, Gong X, Yang K J Vasc Surg Venous Lymphat Disord. 2024; 13(1):101969.

PMID: 39305949 PMC: 11764771. DOI: 10.1016/j.jvsv.2024.101969.

References
1.
Ricci K, Iacobas I . How we approach the diagnosis and management of complex lymphatic anomalies. Pediatr Blood Cancer. 2021; 69 Suppl 3:e28985. DOI: 10.1002/pbc.28985. View

2.
Le Cras T, Mobberley-Schuman P, Broering M, Fei L, Trenor 3rd C, Adams D . Angiopoietins as serum biomarkers for lymphatic anomalies. Angiogenesis. 2016; 20(1):163-173. DOI: 10.1007/s10456-016-9537-2. View

3.
Ji Y, Chen S, Zhou J, Yang K, Zhang X, Xiang B . Sirolimus plus prednisolone vs sirolimus monotherapy for kaposiform hemangioendothelioma: a randomized clinical trial. Blood. 2022; 139(11):1619-1630. DOI: 10.1182/blood.2021014027. View

4.
Foster J, Li D, March M, Sheppard S, Adams D, Hakonarson H . Kaposiform lymphangiomatosis effectively treated with MEK inhibition. EMBO Mol Med. 2020; 12(10):e12324. PMC: 7539180. DOI: 10.15252/emmm.202012324. View

5.
Crane J, Manfredo J, Boscolo E, Coyan M, Takemoto C, Itkin M . Kaposiform lymphangiomatosis treated with multimodal therapy improves coagulopathy and reduces blood angiopoietin-2 levels. Pediatr Blood Cancer. 2020; 67(9):e28529. PMC: 8554683. DOI: 10.1002/pbc.28529. View